Entities / Company
Nektar Therapeutics.
American healthcare company
- Reports this week
- 0
- Active events
- 0
- Connections
- 49
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Earlier this month
-
Multiple financial firms, including KBC Group NV, WINTON GROUP Ltd, and Deutsche Bank, increased their stakes in Nektar Therapeutics on September 12, 2026.Some support1 report
-
Market factors drive comparative business analysis between Nektar Therapeutics and Janux Therapeutics.Some support2 reports
-
Nathan Miller is associated with an investigation involving Nektar Therapeutics.Some support1 report
One to three months ago
-
Nektar Therapeutics is seeking FDA review for its late-stage drug trials.Some support1 report
-
Nektar Therapeutics filed a registration statement with the SEC on July 3, 2025.Some support4 reports1 development inside
-
Nektar Therapeutics is seeking alignment with the FDA for its registrational Phase III study.Some support1 report
-
TD Cowen began coverage of Nektar Therapeutics on July 2, 2026, coinciding with an insider selling 5,538 shares of the company's stock.Some support1 report
Gone quiet
No new reports in 90+ days-
Nektar Therapeutics and Journey Medical are being compared for investment, with Nektar showing stronger consensus rating and upside.Some support1 report
-
Nektar Therapeutics filed required disclosures with the SEC on June 20, 2026.Some support1 report
-
Nektar Therapeutics is headquartered in San Francisco and its pipeline includes a modified CSF protein.Speculative1 report
-
Nektar Therapeutics noted a potential benefit from Trump-era tariffs and onshoring policies.Speculative1 report
-
Nektar Therapeutics' stock doubled following the release of positive trial results.Speculative1 report
-
BTIG raised its price target for Nektar Therapeutics on June 25, 2025.Speculative1 report
-
Nektar Therapeutics announced on July 29, 2025, that a treatment they are developing showed promise by utilizing a unique Treg mechanism.Some support1 report
-
Nektar Therapeutics is headquartered in San Francisco and participated in a conference in New York City on September 4, 2025.Some support3 reports
-
Nektar Therapeutics regained full rights to its rezpeg program from Eli Lilly and Company on August 4, 2025.Some support1 report
-
Nektar Therapeutics received FDA Fast Track designation and saw its stock gain exceed the S&P 500 index gain on August 9, 2025.Well supported3 reports
-
Howard W. Robin was appointed President and CEO of Nektar Therapeutics on August 8, 2025.Some support2 reports
-
Sanofi's disappointing results cleared the way for Nektar Therapeutics.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Nektar Therapeutics this week
News at the entities that move Nektar Therapeutics most-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves Nektar Therapeutics
-
SEC StructuralDHS, DOJ, and SEC formed a joint initiative to establish a Trade Fraud Task Force, setting standards for compliance.Moves Nektar Therapeutics
-
TD Cowen Mentioned togetherAnalyst downgraded Ag Growth International Inc. due to debt management risks.Moves Nektar Therapeutics
-
LinkedIn Mentioned togetherBoth LinkedIn and Google are currently being utilized as platforms for news distribution.Moves Nektar Therapeutics
-
Huntsville Shared contextAn incident occurred in Edna near Houston, and an execution took place in Huntsville, Texas, on September 25, 2026.Moves Nektar Therapeutics
-
Eli Lilly and Company TransactionalExxonMobil, Berkshire Hathaway, and Eli Lilly are top holdings in the Avantis ETF.Moves Nektar Therapeutics
Connections
The 9 strongest of 49, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
FDA Structural
The FDA is formally regulating and evaluating Nektar Therapeutics' drug candidates, including granting Fast Track designation.
-
SEC Structural
Nektar Therapeutics is formally regulated by the SEC, requiring company filings and disclosures to operate.
-
CSF Structural
Nektar Therapeutics utilizes the CSF protein in its development and pipeline.
-
Nathan Miller Operational
Nathan Miller is functionally involved in an investigation concerning the operations of Nektar Therapeutics.
-
Eli Lilly and Company Transactional
Nektar Therapeutics regained full rights to the rezpeg asset from Eli Lilly and Company in 2025.
-
Jonathan Zalevsky Structural
Jonathan Zalevsky is an insider of Nektar Therapeutics, evidenced by stock sales.
-
TD Cowen Mentioned together
TD Cowen has initiated market coverage of Nektar Therapeutics.
-
LinkedIn Mentioned together
Nektar Therapeutics uses LinkedIn as a platform to follow and gather information.
Show all 9 connections
-
Huntsville Shared context
Nektar Therapeutics operates a manufacturing facility located in Huntsville.
History
Events by the month they beganSeptember 2026
2 eventsAugust 2026
3 eventsJuly 2026
1 eventShow 1 earlier month
June 2026
13 events- Nektar Therapeutics filed a registration statement with the SEC on July 3, 2025.
- Nektar Therapeutics and Journey Medical are being compared for investment, with Nektar showing stronger consensus rating and upside.
- Nektar Therapeutics filed required disclosures with the SEC on June 20, 2026.
- Nektar Therapeutics is headquartered in San Francisco and its pipeline includes a modified CSF protein.
- Nektar Therapeutics noted a potential benefit from Trump-era tariffs and onshoring policies.
- Nektar Therapeutics' stock doubled following the release of positive trial results.
- BTIG raised its price target for Nektar Therapeutics on June 25, 2025.
- Nektar Therapeutics announced on July 29, 2025, that a treatment they are developing showed promise by utilizing a unique Treg mechanism.
- Nektar Therapeutics is headquartered in San Francisco and participated in a conference in New York City on September 4, 2025.
- Nektar Therapeutics regained full rights to its rezpeg program from Eli Lilly and Company on August 4, 2025.
- Nektar Therapeutics received FDA Fast Track designation and saw its stock gain exceed the S&P 500 index gain on August 9, 2025.
- Howard W. Robin was appointed President and CEO of Nektar Therapeutics on August 8, 2025.
- Sanofi's disappointing results cleared the way for Nektar Therapeutics.